•
Mar 31, 2023
Rigel Q1 2023 Earnings Report
Reported strong first quarter with increased net product sales and advanced launch of REZLIDHIA.
Key Takeaways
Rigel Pharmaceuticals reported a net loss of $13.5 million for the first quarter of 2023, with total revenues of $26.1 million. The company saw a 47% increase in net product sales compared to Q1 2022, driven by TAVALISSE and REZLIDHIA sales.
Net product sales increased by 47% compared to Q1 2022.
TAVALISSE net product sales increased by 38% from the same period in 2022, reaching $22.3 million.
REZLIDHIA net product sales were $1.5 million.
Net loss decreased to $13.5 million, compared to a net loss of $27.4 million for the same period of 2022.
Rigel
Rigel
Forward Guidance
Rigel has established a strong foundation for its hematology-oncology business to successfully deliver growth in both TAVALISSE and REZLIDHIA, and to advance its development programs.